Skip to content
Colinz Laboratories logo

Colinz Laboratories

531210 BSE
Price unavailable

Colinz Laboratories (COLINZ) share price was ₹69.00 at the 27 Oct 2026 close; market capitalisation ₹17.38 Cr; P/E (TTM) 6.23; sector Healthcare. The share price rose 59.0% over the year to 27 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 21.0% year on year to ₹1.24 Cr and net profit was ₹2.40 Cr, against ₹0.12 Cr a year earlier (compared with Jun 2025). Promoters held 50.60% of Colinz Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 62/100 (Good) as of 28 Oct 2026.

Close 27 Oct 2026 ₹69.00 +28.00 +68.29% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹17.38 Cr
P/E (TTM)
6.23
EBITDA
₹90.00 L
Return on Equity
5.12%
Debt to Equity
0.04
Book Value
₹39.87
EPS (TTM)
₹11.08
52W High
₹87.91
52W Low
₹36.11

Price-based figures as of 27 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.1035.034,23,747 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,625.0087.362,55,514 Cr15.240.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,599.5072.211,74,950 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,182.30107.821,17,912 Cr22.250.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,179.9026.261,17,695 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.0034.711,11,847 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.6032.841,10,725 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Colinz Laboratories (this company)
—6.2317 Cr1.730.00%5.12%7.20%9 Cr3 Cr
Median 8 companies₹1,766.1034.871,17,804 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

62 Good
Overall score

Data confidence 98/100

Category scores

Quality Good 59
Returns, margins, earnings quality 22% weight
Valuation Strong 77
Cheap vs sector & own history 24% weight
Growth Poor 26
Sales & profit trajectory 9% weight
Financial Health Strong 76
Solvency, leverage, coverage 9% weight
Momentum Strong 88
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -15.4%
  • The company has delivered a poor sales growth of -0.07% over past five years.
  • Company has a low return on equity of 5.41% over last 3 years.

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

Bearish

Bearish
9
Neutral
5
Bullish
5

Moving Averages

Bearish

Bearish
6
Neutral
0
Bullish
4

Growth Rate

Revenue Growth
-2.94% higher than 3Y

change over 1 year

Net Income Growth
0% lower than 3Y

change over 1 year

Cash Flow Change
275%

change over 1 year

EBITDA Margin Change
15.92%

change over 1 year Operating margin 4.84% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1.9
1.79
1.71
1.63
1.75
1.86
1.47
1.45
1.57
1.39
1.43
1.75
1.24
Expenses
1.74
1.67
1.57
1.51
1.59
1.69
1.4
1.35
1.44
1.31
1.33
1.66
1.18
Operating Profit
0.16
0.12
0.14
0.12
0.16
0.17
0.07
0.1
0.13
0.08
0.1
0.09
0.06
OPM %
8.42%
6.7%
8.19%
7.36%
9.14%
9.14%
4.76%
6.9%
8.28%
5.76%
6.99%
5.14%
4.84%
Other Income
0.04
0.08
0.05
0.11
0.07
0.08
0.08
0.08
0.08
0.16
0.08
0.17
2.89
Interest
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
Depreciation
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.04
0.04
PBT
0.16
0.16
0.15
0.19
0.19
0.21
0.11
0.13
0.16
0.19
0.13
0.21
2.9
Tax %
18.75%
25%
26.67%
31.58%
26.32%
23.81%
45.45%
-23.08%
25%
26.32%
30.77%
19.05%
17.24%
Net Profit
0.12
0.12
0.11
0.14
0.14
0.16
0.05
0.15
0.12
0.14
0.08
0.17
2.4
EPS (₹)
0.48
0.48
0.44
0.56
0.56
0.64
0.2
0.6
0.48
0.56
0.32
0.67
9.53
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
7.88
8.1
8.05
7.83
7.59
7.53
6.16
6.97
7.15
7.03
6.53
6.14
5.81
Expenses
7.42
7.65
7.64
7.48
7.24
7.22
5.82
6.38
6.52
6.49
6.04
5.72
5.48
Operating Profit
0.46
0.45
0.41
0.35
0.35
0.31
0.34
0.59
0.63
0.54
0.49
0.42
0.33
OPM %
5.84%
5.56%
5.09%
4.47%
4.61%
4.12%
5.52%
8.46%
8.81%
7.68%
7.5%
6.84%
5.68%
Other Income
0.1
0.1
0.09
0.1
0.12
0.13
0.19
0.17
0.15
0.28
0.3
0.48
3.3
Interest
0.12
0.12
0.12
0.08
0.1
0.07
0.09
0.08
0.05
0.04
0.04
0.05
0.04
Depreciation
0.3
0.28
0.27
0.22
0.22
0.19
0.19
0.2
0.13
0.13
0.13
0.16
0.16
PBT
0.14
0.15
0.11
0.15
0.15
0.18
0.25
0.48
0.6
0.65
0.62
0.69
3.43
Tax %
35.71%
40%
-27.27%
-53.33%
26.67%
27.78%
16%
29.17%
23.33%
26.15%
20.97%
24.64%
—
Net Profit
0.1
0.09
0.14
0.23
0.12
0.13
0.21
0.34
0.46
0.49
0.5
0.51
2.79
EPS (₹)
0.22
0.2
0.31
0.5
0.26
0.28
0.46
0.74
1.83
1.95
1.98
2.02
11.08
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3.54
3.54
3.54
3.54
3.54
3.54
3.55
3.55
2.52
2.52
2.52
2.52
Reserves
2.62
2.71
2.98
3.21
3.3
3.29
3.75
4.14
5.62
6.43
6.96
7.52
Borrowings
2.53
1.8
0.76
0.42
0.68
0.38
0.99
0.48
0.27
0.57
0.64
0.39
Other Liabilities
1.97
1.7
2.4
2.42
1.65
1.6
1.81
1.76
1.82
1.84
1.7
2.35
Total Liabilities
10.66
9.75
9.68
9.59
9.17
8.81
10.1
9.93
10.23
11.36
11.82
12.78
Fixed Assets
3.16
2.88
2.63
2.41
2.21
2.06
2.03
1.86
1.71
1.58
1.7
1.54
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0.29
0.29
0.41
0.53
0.5
0.36
0.61
0.67
0.66
1.02
1.04
1.11
Other Assets
7.21
6.58
6.64
6.65
6.46
6.39
7.46
7.4
7.86
8.76
9.08
10.13
Total Assets
10.66
9.75
9.68
9.59
9.17
8.81
10.1
9.93
10.23
11.36
11.82
12.78
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.09
0.58
0.06
0.34
0.12
0.58
2.16
0.47
0.4
1.03
-1.45
2.54
Investing
0.03
0
-0.01
-0.11
-0.01
-0.04
-0.16
-0.03
0.01
0.01
-0.23
0.01
Financing
0.45
-0.73
-0.03
0.01
0.02
0.06
0.08
0.09
0.11
0.23
0.24
0.43
Net Cash Flow
0.57
-0.16
0.02
0.24
0.12
0.6
2.07
0.52
0.52
1.27
-1.45
2.98
Free Cash Flow
0.09
0.58
0.04
0.34
0.12
0.54
2
0.43
0.4
1.03
-1.71
2.54
CFO/OP
26
136
22
106
43
210
659
105
89
224
-253
650
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62.53
60.83
66.65
78.31
80.79
72.22
77.03
63.36
57.69
44.65
36.89
49.93
Inventory Days
289
232
267
266
247
225
208
148
149
134
136
149
Days Payable
116
60.66
55.68
91.93
44.16
49.29
90
76.17
103
94.81
94.31
80.64
Cash Conversion Cycle
235
232
278
253
283
248
195
135
104
84.15
78.81
118
Working Capital Days
110
100
71.19
72.72
89.45
79.01
0
9.95
11.23
-22.84
73.22
-60.64
ROCE %
3.2%
3.23%
3%
3.18%
3.4%
3.39%
4.39%
6.8%
8.08%
7.7%
6.62%
7.2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Colinz Laboratories insights

61 extracted metrics + investor summaries across FY08–FY27.

Shareholding Pattern

Promot.50.60%Others2.50%Public46.90%As ofSep 2026

Documents

Frequently Asked Questions about Colinz Laboratories

What does Colinz Laboratories Ltd do?
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]
Where is Colinz Laboratories Ltd (COLINZ) listed?
Colinz Laboratories Ltd trades under code 531210 on the BSE.
Which sector does Colinz Laboratories Ltd belong to?
Colinz Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Colinz Laboratories Ltd?
Colinz Laboratories Ltd has a market capitalisation of ₹17.38 Cr as of 27 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Colinz Laboratories Ltd?
Colinz Laboratories Ltd trades at a PE ratio of 6.23 as of 27 Oct 2026, on earnings per share of ₹11.08, against a book value of ₹39.87 per share.
What is the 52-week high and low of Colinz Laboratories Ltd?
Over the last 52 weeks Colinz Laboratories Ltd has traded between ₹36.11 and ₹87.91 as of 27 Oct 2026.
What is the Return on Equity (ROE) of Colinz Laboratories Ltd?
Colinz Laboratories Ltd reported a return on equity of 5.12%. Its debt-to-equity ratio is 0.04.

Company Information

Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]

Website colinz.com
Face Value ₹ 10
Shares Outstanding 25,18,814

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531210.md for Colinz Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month